MY AMERICAN SCIENTIST
LOG IN! REGISTER!
SEARCH
 
RSS
Logo IMG
HOME > SCIENCE IN THE NEWS > Science Detail

SCIENCE IN THE NEWS DAILY

Melanoma Drug Combo Packs a One-Two Punch

from ScienceNOW Daily News

Drug resistance is the bane of cancer researchers and patients. But early results from a new clinical trial suggest a way to get around a tumor's defenses. By combining high doses of two new drugs against advanced melanoma, scientists were able to delay for months the cancer's ability to evade the therapy aimed at a tumor's molecular weak spot.

The trial is testing a so-called BRAF inhibitor, a widely heralded new type of melanoma drug. It targets a growth-spurring protein, BRAF, encoded by a mutation in the BRAF gene that occurs in about half of melanoma patients. Although the drug extends patients' lives--on average they live 14 to 15 months, versus 8 months on conventional therapy--their tumors eventually develop resistance and begin growing again. Often the tumors restore the BRAF growth pathway by turning on a downstream protein called MEK, suggesting that combining a MEK inhibitor and a BRAF inhibitor could stave off cancer growth longer.

That strategy now shows signs of working, according to data released today in advance of the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, from 1-5 June. In 77 patients who took a BRAF inhibitor and a MEK inhibitor made by GlaxoSmithKline, the drugs shrank tumors or delayed growth by 7.4 months on average--no longer than has been reported for the BRAF inhibitor alone. But the results were more encouraging for 24 patients who received the highest doses of the two drugs. Their tumors became stable or shrank and did not resume growing for 10.8 months on average.

Read more...

 

Connect With Us:

    Pinterest Icon Google+ Icon Twitter Icon Facebook Icon Sm


Subscribe to Our Content!

Visit our RSS Feeds page to choose among 13 customized feeds, or create a free My AmSci account to request an email notice whenever a specified author, department or discipline appears online.


Subscribe to Free eNewsletters!

  • Sigma Xi SmartBrief:

    A free daily summary of the latest news in scientific research. Each story is summarized concisely and linked directly to the original source for further reading.

  • American Scientist Update

  • An early peek at each new issue, with descriptions of feature articles, columns, Science Observers and more. Every other issue contains links to everything in the latest issue's table of contents.

  • Scientists' Nightstand

  • News of book reviews published in American Scientist and around the web, as well as other noteworthy happenings in the world of science books.

    To sign up for automatic emails of the American Scientist Update and Scientists' Nightstand issues, create an online profile, then sign up in the My AmSci area.


EMAIL TO A FRIEND :

Of Possible Interest

Science In The News Daily: Three Doctors Charged in Armstrong Doping Case

Science In The News Daily: Antibody Cocktail Cures Monkeys of Ebola

Science In The News Daily: Diesel Exhausts Do Cause Cancer, Says WHO

Subscribe to American Scientist